سعر انتيريترو 200 مجم 10كبسول 2022

Efavirenz 200 mg capsules, pack of 10; non-nucleoside reverse transcriptase inhibitor for HIV-1 (listed as '(n/a yet)', i.e. not yet available, in the source sheet).

• Treatment of HIV-1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg, in combination with other antiretroviral agents.Population: Adults and children ≥3 months and ≥3.5 kgDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>5%, moderate to severe): impaired concentration, abnormal dreams, rash, dizziness, nausea, headache, fatigue, insomnia and vomiting.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Previously demonstrated clinically significant hypersensitivity (e.g. Stevens-Johnson syndrome, erythema multiforme or toxic skin eruptions) to any component.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Coadministration with elbasvir and grazoprevir.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• QTc prolongation has been observed; consider alternatives in patients at higher risk of torsade de pointes or receiving drugs with known torsade risk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Must not be used as a single agent or added as a sole agent to a failing regimen; should not be coadministered with fixed-dose combinations already containing efavirenz.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Serious psychiatric symptoms (severe depression, suicidal ideation, aggressive behavior, paranoid and manic reactions) and nervous system symptoms (53% of adults; dizziness, insomnia, impaired concentration, somnolence, abnormal dreams) have been reported; late-onset neurotoxicity including ataxia and encephalopathy may occur.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A substrates, inducers and inhibitorsEfavirenz induces CYP3A and CYP2B6 and can alter concentrations of many drugs; coadministration with elbasvir/grazoprevir is contraindicated; other drugs may need dose adjustment (see US label Table 7).DailyMed (U.S. National Library of Medicine)
• Hormonal contraceptives (ethinyl estradiol/norgestimate, etonogestrel implant)Decreased exposure of contraceptive hormones; a reliable barrier method should be used in addition to hormonal contraceptives; contraceptive failure with etonogestrel has been reported.DailyMed (U.S. National Library of Medicine)
• VoriconazoleEfavirenz significantly decreases voriconazole levels and voriconazole increases efavirenz levels; adjust doses (voriconazole 400 mg every 12 hours, efavirenz 300 mg daily).DailyMed (U.S. National Library of Medicine)

• There are retrospective case reports of neural tube defects in infants of women exposed to efavirenz in the first trimester; prospective registry data do not show an increased overall birth-defect risk. Perform pregnancy testing before initiation and advise adolescents and adults of childbearing potential to use effective contraception (barrier plus other method) during treatment and for 12 weeks after stopping.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Efavirenz is present in human milk; because of the potential for HIV-1 transmission, developing viral resistance and adverse reactions in the infant, breastfeeding is not recommended in the US label.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Efavirenz: Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1; activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase; HIV-2 reverse transcriptase and human DNA polymerases are not inhibited.